Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy (CHILd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03973359
Recruitment Status : Recruiting
First Posted : June 4, 2019
Last Update Posted : June 4, 2019
Sponsor:
Collaborator:
Fondazione Regionale per la Ricerca Biomedica (FRRB) - Regione Lombardia
Information provided by (Responsible Party):
Daniele Lilleri, Foundation IRCCS San Matteo Hospital

Brief Summary:

Human cytomegalovirus (HCMV) is the leading infectious agent causing congenital disabilities such as mental retardation, psychomotor delay, hearing loss, speech and language disabilities, behavioural disorders and visual impairment. About 0.6% newborns are HCMV-congenitally infected and, among these, about 20% are symptomatic at birth or will develop long-term sequelae. The public health impact of congenital HCMV is substantial although greatly unrecognized. In Italy, estimated direct costs per affected child exceed €100.000 for a total of €60-70M. HCMV is also a significant cause of infection/disease in the immunocompromised host.

Epidemiological studies and population-based models have preliminarily documented that most of the burden associated to congenital HCMV would be due to non-primary maternal infection. Presently, reinfections are believed to be responsible for the great majority of infected fetuses born to immune mothers.

This study addresses incidence, outcome and prevention of congenital HCMV infection in seropositive pregnant women.The study includes 2 parts: part 1 in which the incidence and outcome of congenital HCMV is investigated in a large population of HCMV seropositive pregnant women and HCMV shedding and immune response is closely monitored in a subset of participants (nested study); part 2 in which the efficacy of an hygiene intervention is assessed.


Condition or disease Intervention/treatment Phase
Congenital Cytomegalovirus Infection Maternal Cytomegalovirus Infection Behavioral: Hygienic recommendations Not Applicable

Detailed Description:

Part 1. Epidemiologic study. To investigate incidence and outcome of congenital infection in immune mothers, clinical records of pregnant women are reviewed for HCMV serostatus at ≤ 13 weeks' gestation. Women with HCMV serology compatible with a remote infection are asked to participate in the study. Consenting women are given a pre-stamped, pre-addressed envelope containing a swab to collect newborn's saliva. Envelopes are sent by courier to a centralized diagnostic facility for HCMV testing.

Women can also be enrolled at delivery, provided that the woman has records of presence of virus-specific IgG and absence of IgM early during gestation(or in a previous pregnancy) or, in case of unknown serostatus, a sample of serum/plasma stored at ≤ 13 weeks' gestation is available for retrospective antibody testing (retrospective part of the epidemiology study).

Part 1. Nested study. A subset of IgG pos IgM neg women selected among those enrolled at ≤13 weeks' gestation in the epidemiology study are included in a nested study. These women are monitored at enrolment, 20, 30 weeks of gestation and at delivery by prospective determination of HCMV DNA excretion in different bodily fluids. In DNA-positive specimens selected HCMV genes will be sequenced.

Part 2. Prevention study. To assess the effectiveness of hygiene measures for prevention of congenital infection HCMV seropositive pregnant women are enrolled at ≤ 13 weeks' gestation. Part 2 starts when enrolment of Part 1 is completed. In practice, part 2 is a continuation of part 1 with the only addition of delivering hygiene information at enrolment.

Part 2 will not be performed in case congenital infection rate in Part 1 is <0.4% and clear maternal risk factor for intrauterine transmission cannot be identified at interim analysis (i.e. after examination of 5000 newborns).

In case HCMV DNA is detected in newborn's saliva, a urine sample is obtained for confirmation of congenital infection. Infants with documented congenital infection are clinically assessed at the time of diagnosis (for Part 1 and 2) and at one year of age (Part 1 only).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 23500 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Incidence, Outcome and Prevention of Congenital Human Cytomegalovirus (HCMV) Infection in HCMV-seropositive Pregnant Women
Actual Study Start Date : September 4, 2017
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
No Intervention: Epidemiology
HCMV-seropositive pregnant women receiving standard care
Experimental: Prevention
HCMV-seropositive pregnant women receiving hygienic information
Behavioral: Hygienic recommendations
Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.




Primary Outcome Measures :
  1. Part 1. Epidemiology study. Incidence and clinical outcome of congenital HCMV infection in pregnant women with preconception immunity. [ Time Frame: Within 21 days of life ]
    Number of infants with ascertained congenital infection.

  2. Part 2. Prevention study. Efficacy of hygiene counseling in reducing congenital HCMV infection in pregnant women with preconception immunity. [ Time Frame: Within 21 days of life ]
    Number of infants with ascertained congenital infection born to HCMV seropositive women informed about hygiene measures compared to the number of newborns with congenital infection diagnosed in Part 1.


Secondary Outcome Measures :
  1. Frequency of non-primary infections during pregnancy (Nested study) [ Time Frame: 10, 20, 30, 40 gestation weeks ]
    Number of participants with HCMV non-primary infection. HCMV non-primary infection is defined as detection of HCMV DNA shedding in bodily fluids.

  2. Frequency of HCMV re-infections vs re-activations during pregnancy (Nested study) [ Time Frame: 10, 20, 30, 40 gestation weeks ]
    Number of participants with HCMV re-infection or re-activation. Re-infection is defined as the appearance of genetically distinct HCMV strains; Reactivation is defined as the sustained presence of the same strain.

  3. Antigen-specific IgG levels in non-primary infection during pregnancy (Nested study) [ Time Frame: 10, 20, 30, 40 gestation weeks ]
    Levels of antigen-specific IgG in participants with or w/o non-primary infection.

  4. Antigen-specific IgM levels in non-primary infection during pregnancy (Nested study) [ Time Frame: 10, 20, 30, 40 gestation weeks ]
    Levels of antigen-specific IgM in participants with or w/o non-primary infection.

  5. Neutralizing antibody titers in non-primary infection during pregnancy (Nested study) [ Time Frame: 10, 20, 30, 40 gestation weeks ]
    Titers of neutralizing antibodies in participants with or w/o non-primary infection.

  6. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Age [ Time Frame: Delivery ]
    Age in mothers of newborns with or w/o congenital HCMV infection

  7. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Country of origin [ Time Frame: Delivery ]
    Country of origin of mothers of newborns with or w/o congenital HCMV infection

  8. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Occupation [ Time Frame: Delivery ]
    Occupation of mothers of newborns with or w/o congenital HCM infection

  9. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Contact with young children [ Time Frame: Delivery ]
    Contact with children <36 months in mothers of newborns with or w/o congenital HCMV infection

  10. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Twin pregnancy [ Time Frame: Delivery ]
    Twin vs singleton pregnancy in mothers of newborns with or w/o congenital HCMV infection

  11. Risk factors for congenital HCMV infection in pregnant women with preconception immunity. Concomitant pathologies [ Time Frame: Delivery ]
    Concomitant pathologies in mothers of newborns with or w/o congenital HCMV infection



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult (≥ 18 years old) pregnant women at ≤13 weeks gestation
  • Presence of HCMV IgG and absence of IgM or presence of high avidity IgG with or without IgM
  • Presence of HCMV-specific IgG and absence of IgM or presence of high avidity IgG in case of positive IgM at ≤13 weeks gestation documented by medical report or by retrospective antibody determination on samples stored at ≤13 weeks (for women enrolled at delivery)
  • Willingness to participate in the study
  • Ability to understand information material
  • Written informed consent

Exclusion Criteria:

  • Unreliable women as judged by the investigator
  • Women not willing to give written consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03973359


Contacts
Layout table for location contacts
Contact: Daniele Lilleri, MD +39 0382 501501 d.lilleri@smatteo.pv.it
Contact: Gabriela Cassinelli, PhD +39 0382 502682 g.cassinelli@smatteo.pv.it

Locations
Layout table for location information
Italy
ASST Spedali Civili di Brescia Recruiting
Brescia, Italy, 25123
Contact: Federico Prefumo, MD         
Poliambulanza Brescia Recruiting
Brescia, Italy, 25124
Contact: Giorgio Pagani, MD         
ASST Vimercate (Ospedale di Carate Brianza) Recruiting
Carate Brianza, Italy, 20841
Contact: Anna Locatelli, MD         
ASST Monza (presidio di Desio) Recruiting
Desio, Italy, 20832
Contact: Simona Rutolo, MD         
Fondazione IRCCS Ospedale Maggiore Policlinico Recruiting
Milan, Italy, 20122
Contact: Beatrice Tassis, MD         
Ospedale Macedonio Melloni (ASST FBF-Sacco) Recruiting
Milan, Italy, 20129
Contact: Michele Vignali, MD         
Ospedale San Raffaele Recruiting
Milan, Italy, 20132
Contact: Paolo Cavoretto, MD         
Ospedale Buzzi (ASST FBF-Sacco) Recruiting
Milan, Italy, 20154
Contact: Irene Cetin, MD         
Ospedale Sacco (ASST FBF-Sacco) Recruiting
Milan, Italy, 20157
Contact: Valeria Savasi, MD         
Fondazione Monza Brianza per il Bambino e la sua Mamma Recruiting
Monza, Italy, 20900
Contact: Patrizia Vergani, MD         
Fondazione IRCCS Policlinico San Matteo Recruiting
Pavia, Italy
Contact: Arsenio Spinillo, MD         
ASST dei Sette Laghi (Ospedale Filippo Del Ponte) Active, not recruiting
Varese, Italy, 21100
Sponsors and Collaborators
Foundation IRCCS San Matteo Hospital
Fondazione Regionale per la Ricerca Biomedica (FRRB) - Regione Lombardia
Investigators
Layout table for investigator information
Principal Investigator: Daniele Lilleri, MD Fondazione IRCCS Policlinico San Matteo

Layout table for additonal information
Responsible Party: Daniele Lilleri, Principal Investigator, Foundation IRCCS San Matteo Hospital
ClinicalTrials.gov Identifier: NCT03973359     History of Changes
Other Study ID Numbers: 20170011101
First Posted: June 4, 2019    Key Record Dates
Last Update Posted: June 4, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases